21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia

Inclusion Criteria: * Consent informed, written, signed and dated * Women or men aged 18 to 70 years inclusive * Carrier of L. loa microfilaremia * Body weight ≥ 40 kg and less than 90 kg Exclusion Criteria: * Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of albendazole placebo) * Any vaccination within 4 weeks previous to this study * Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment) * Known immunosuppressive pathology (by self-report) * Past or present history of neurological (including epilepsy) or neuropsychiatric disease * Current treatment with ritonavir and/or rifampicin * Use of cocaine or other drugs of abuse in the 72 hours preceding administration of the trial treatment, as determined by history during the medical interview * Past or present history of liver, kidney or bone marrow failure * ALAT transaminase level ≥ 3 times the upper limit of normal (3N) according to laboratory standards * Any condition, in the opinion of the investigator, that exposes the subject to undue risk * Known intolerance to ALB or benzimidazole derivatives in general * Subjects who donated blood in the previous 8 weeks to study entry, with a standard volume (500 mL) * On clinical examination…